Your browser doesn't support javascript.
loading
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.
Colen, Rivka R; Fujii, Takeo; Bilen, Mehmet Asim; Kotrotsou, Aikaterini; Abrol, Srishti; Hess, Kenneth R; Hajjar, Joud; Suarez-Almazor, Maria E; Alshawa, Anas; Hong, David S; Giniebra-Camejo, Dunia; Stephen, Bettzy; Subbiah, Vivek; Sheshadri, Ajay; Mendoza, Tito; Fu, Siqing; Sharma, Padmanee; Meric-Bernstam, Funda; Naing, Aung.
Afiliação
  • Colen RR; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rcolen@mdanderson.org.
  • Fujii T; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. rcolen@mdanderson.org.
  • Bilen MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4004, USA.
  • Kotrotsou A; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Abrol S; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hess KR; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Hajjar J; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Suarez-Almazor ME; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Alshawa A; Department of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, USA.
  • Hong DS; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Giniebra-Camejo D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4004, USA.
  • Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4004, USA.
  • Subbiah V; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Sheshadri A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4004, USA.
  • Mendoza T; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4004, USA.
  • Fu S; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sharma P; Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4004, USA.
  • Naing A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Invest New Drugs ; 36(4): 601-607, 2018 08.
Article em En | MEDLINE | ID: mdl-29075985
ABSTRACT
We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia / Imunoterapia Tipo de estudo: Etiology_studies / Prognostic_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia / Imunoterapia Tipo de estudo: Etiology_studies / Prognostic_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article